CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
靶向 PRAME 治疗急性髓系白血病
英文原题：Targeting PRAME for acute myeloid leukemia therapy.
查看英文原题
Targeting PRAME for acute myeloid leukemia therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
尽管急性髓系白血病（AML）的靶向治疗取得了显著进展，但老年患者、疾病特征不适合的患者以及具有不良疾病风险特征的患者，其临床结局仍令人失望。过去10年间，过继性T细胞免疫治疗已被认为是治疗多种恶性肿瘤的一种策略。然而，它在AML中面临重大挑战，主要因为髓系原始细胞不含有独特的表面抗原。黑色素瘤优先表达抗原（PRAME）是一种癌-睾丸抗原，在AML中异常表达，且不存在于正常造血细胞中。越来越多的证据表明，PRAME是治疗AML的有用靶点。本文综述了PRAME的结构和功能、其对正常细胞和AML原始细胞的影响、其在预后和随访中的意义，以及其在AML抗原特异性免疫治疗中的应用。
展开英文摘要原文
Despite significant progress in targeted therapy for acute myeloid leukemia (AML), clinical outcomes are disappointing for elderly patients, patients with less fit disease characteristics, and patients with adverse disease risk characteristics. Over the past 10 years, adaptive T-cell immunotherapy has been recognized as a strategy for treating various malignant tumors.
However, it has faced significant challenges in AML, primarily because myeloid blasts do not contain unique surface antigens. The preferentially expressed antigen in melanoma (PRAME), a cancer-testis antigen, is abnormally expressed in AML and does not exist in normal hematopoietic cells.
Accumulating evidence has demonstrated that PRAME is a useful target for treating AML. This paper reviews the structure and function of PRAME, its effects on normal cells and AML blasts, its implications in prognosis and follow-up, and its use in antigen-specific immunotherapy for AML.
论文信息
- 作者
- Yang J、Chen M、Ye J、Ma H
- 单位
- Department of Hematology and Institute of Hematology, West China Hospital, Sichuan University, Chengdu, China.China
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Frontiers in immunology2024
- 原文标识
- PubMed 38596687 · DOI 10.3389/fimmu.2024.1378277
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →